Calcitriol blunts the deleterious impact of advanced glycation end products on endothelial cells

American Journal of Physiology - Renal Physiology

Volumn 294, Issue 5, 2008, Pages

  Talmor, Yeela ^a,b   Golan, Eliezer ^a,b   Benchetrit, Sydney ^a,b   Bernheim, Jacques ^a,b   Klein, Osnat ^a,b   Green, Janice ^a   Rashid, Gloria ^a  

^a MEIR MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Advanced glycation end products; Endothelial cells; Nuclear factor B; Vitamin D

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; CALCITRIOL; DNA; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HUMAN SERUM ALBUMIN; I KAPPA B ALPHA; INTERLEUKIN 6; MESSENGER RNA; TRANSCRIPTION FACTOR RELA; ADVANCED GLYCOSYLATION END PRODUCT RECEPTOR; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; BOVINE SERUM ALBUMIN; CALCIUM CHANNEL STIMULATING AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN RECEPTOR; RNA;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL PROTECTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; ENDOTHELIUM CELL; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; INFLAMMATION; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN PHOSPHORYLATION; UPREGULATION; BIOSYNTHESIS; CELL CULTURE; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; METABOLISM; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

BLOTTING, WESTERN; CALCITRIOL; CALCIUM CHANNEL AGONISTS; CELLS, CULTURED; ENDOTHELIAL CELLS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INFLAMMATION; INTERLEUKIN-6; NF-KAPPA B; NITRIC OXIDE SYNTHASE TYPE III; RECEPTORS, IMMUNOLOGIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; SERUM ALBUMIN, BOVINE; SIGNAL TRANSDUCTION;

EID: 45149124344     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00051.2008     Document Type: Article

References (40)

1. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 318: 1315-1321, 1988.
2. Bucala R, Cerami A. Advanced glycosylation: chemistry, biology, and implications for diabetes and aging. Adv Pharmacol 23: 1-34, 1992.
3. Chakravarthy U, Hayes RG, Stitt AW, McAuley E, Archer DB. Constitutive nitric oxide synthase expression in retinal vascular endothelial cells is suppressed by high glucose and advanced glycation end products. Diabetes 47: 945-952, 1998.
4. Chiu KC, Chu A, Go VL, Saad MF. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr 79: 820-825, 2004.
5. Cohen-Lahav M, Shany S, Tobvin D, Chaimovitz C, Douvdevani A. Vitamin D decreases NFkappaB activity by increasing IkappaBalpha levels. Nephrol Dial Transplant 21: 889-897, 2006.
6. Duncan BB, Schmidt MI, Pankow JS, Ballantyne CM, Couper D, Vigo A, Hoogeveen R, Folsom AR, Heiss G. Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes 52: 1799-1805, 2003.
7. Ford ES, Ajani UA, McGuire LC, Liu S. Concentrations of serum vitamin D and the metabolic syndrome among U.S adults. Diabetes Care 28: 1228-1230, 2005.
8. Galley HF, Webster NR. Physiology of the endothelium. Br J Anaesth 93: 105-113, 2004.
9. Harant H, Andrew PJ, Reddy GS, Foglar E, Lindley IJ. 1alpha,25-dihydroxyvitamin D3 and a variety of its natural metabolites transcriptionally repress nuclear-factor-kappaB-mediated interleukin-8 gene expression. Eur J Biochem 250: 63-71, 1997.
10. Hayden MS, Ghosh S. Signaling to NF-kappaB. Genes Dev 18: 2195-2224, 2004.
11. Hu FB, Meigs JB, Li TY, Rifai N, Manson JE. Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes 53: 693-700, 2004.
12. Khan BV, Harrison DG, Olbrych MT, Alexander RW, Medford RM. Nitric oxide regulates vascular cell adhesion molecule 1 gene expression and redox-sensitive transcriptional events in human vascular endothelial cells. Proc Natl Acad Sci USA 93: 9114-9119, 1996.
13. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA 88: 4651-4655, 1991.
14. Maestro B, Campion J, Davila N, Calle C. Stimulation by 1,25-dihydroxyvitamin D3 of insulin receptor expression and insulin responsiveness for glucose transport in U-937 human promonocytic cells. Endocr J 47: 383-391, 2000.
15. Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik E, Delaney V, Friedman EA, Cerami A, Vlassara H. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 325: 836-842, 1991.
16. Mantell DJ, Owens PE, Bundred NJ, Mawer EB, Canfield AE. 1 Alpha,25-dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. Circ Res 87: 214-220, 2000.
17. Mathieu C, Badenhoop K. Vitamin D and type 1 diabetes mellitus: state of the art. Trends Endocrinol Metab 16: 261-266, 2005.
18. O'Riordan E, Chen J, Brodsky SV, Smirnova I, Li H, Goligorsky MS. Endothelial cell dysfunction: the syndrome in making. Kidney Int 67: 1654-1658, 2005.
19. Park CW, Oh YS, Shin YS, Kim CM, Kim YS, Kim SY, Choi EJ, Chang YS, Bang BK. Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 33: 73-81, 1999.
20. Pittas AG, Lau J, Hu FB, Dawson-Hughes B. The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J Clin Endocrinol Metab 92: 2017-2029, 2007.
21. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286: 327-334, 2001.
22. Raj DS, Choudhury D, Welbourne TC, Levi M. Advanced glycation end products: a Nephrologist's perspective. Am J Kidney Dis 35: 365-380, 2000.
23. Rashid G, Benchetrit S, Fishman D, Bernheim J. Effect of advanced glycation end-products on gene expression and synthesis of TNF-alpha and endothelial nitric oxide synthase by endothelial cells. Kidney Int 66: 1099-1106, 2004.
24. Rojas A, Romay S, Gonzalez D, Herrera B, Delgado R, Otero K. Regulation of endothelial nitric oxide synthase expression by albumin-derived advanced glycosylation end products. Circ Res 86: E50-E54, 2000.
25. Schmidt AM, Hori O, Brett J, Yan SD, Wautier JL, Stern D. Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler Thromb 14: 1521-1528, 1994.
26. Schmidt AM, Hori O, Cao R, Yan SD, Brett J, Wautier JL, Ogawa S, Kuwabara K, Matsumoto M, Stern D. RAGE: a novel cellular receptor for advanced glycation end products. Diabetes 45, Suppl 3: S77-S80, 1996.
27. Schmidt AM, Hori O, Chen JX, Li JF, Crandall J, Zhang J, Cao R, Yan SD, Brett J, Stern D. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 96: 1395-1403, 1995.
28. Scragg R, Sowers M, Bell C. Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the Third National Health and Nutrition Examination Survey. Diabetes Care 27: 2813-2818, 2004.
29. Shah V, Wiest R, Garcia-Cardena G, Cadelina G, Groszmann RJ, Sessa WC. Hsp90 regulation of endothelial nitric oxide synthase contributes to vascular control in portal hypertension. Am J Physiol Gastrointest Liver Physiol 277: G463-G468, 1999.
30. Shoji T, Shinohara K, Kimoto E, Emoto M, Tahara H, Koyama H, Inaba M, Fukumoto S, Ishimura E, Miki T, Tabata T, Nishizawa Y. Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant 19: 179-184, 2004.
31. Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: a review. Diabetologia 44: 129-146, 2001.
32. Szmitko PE, Wang CH, Weisel RD, de Almeida JR, Anderson TJ, Verma S. New markers of inflammation and endothelial cell activation: Part I. Circulation 108: 1917-1923, 2003.
33. Talmor Y, Rashid G, Green J, Klein O, Bernheim J. Calcitriol blunts the endothelial mRNA expressions of eNOS, VEGF, RAGE and IL-6 secretion (Abstract). Nephrol Dial Trasplant 21: IV21, 2006.
34. Urban MB, Baeuerle PA. The role of the p50 and p65 subunits of NF-kappa B in the recognition of cognate sequences. New Biol 3: 279-288, 1991.
35. Vlassara H, Bucala R, Striker L. Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest 70: 138-151, 1994.
36. Vlassara H, Fuh H, Donnelly T, Cybulsky M. Advanced glycation endproducts promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbits. Mol Med 1: 447-456, 1995.
37. Wautier JL, Schmidt AM. Protein glycation: a firm link to endothelial cell dysfunction. Circ Res 95: 233-238, 2004.
38. Xiang W, Kong J, Chen S, Cao LP, Qiao G, Zheng W, Liu W, Li X, Gardner DG, Li YC. Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab 288: E125-E132, 2005.
39. Zehnder D, Bland R, Chana RS, Wheeler DC, Howie AJ, Williams MC, Stewart PM, Hewison M. Synthesis of 1,25-dihydroxyvitamin D(3) by human endothelial cells is regulated by inflammatory cytokines: a novel autocrine determinant of vascular cell adhesion. J Am Soc Nephrol 13: 621-629, 2002.
40. Zhang FL, Gao HQ, Shen L. Inhibitory effect of GSPE on RAGE expression induced by advanced glycation end products in endothelial cells. J Cardiovasc Pharmacol 50: 434-440, 2007.